Navigation Links
An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
Date:3/10/2010

WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an acute migraine therapy that is not contraindicated in patients with a history, symptoms or signs of vascular disease and also offers improved efficacy and fast-acting oral delivery would earn a 45 percent patient share in the treatment of migraine, according to surveyed U.S. neurologists. In Europe, such an agent would earn a 30 percent patient share, according to surveyed European neurologists.


'/>"/>
SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
(Date:7/30/2014)... PISCATAWAY, N.J. , July 30, 2014  InnoPharma, ... for Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), ... of agitation and disturbed behaviors in patients with schizophrenia ... of this generic injectable drug, InnoPharma has entered into ... Sandoz Canada will make, use, sell, market ...
Breaking Medicine Technology:Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... a large,randomized clinical trial for patients with newly ... marrow, has,shown that the use of a low ... with lenalidomide (Revlimid ®),is associated with improved survival ... a higher, standard dose of,dexamethasone. The clinical trial ...
... Programs to be Presented, SOUTH SAN FRANCISCO, Calif., ... four posters containing non-clinical data will be,presented at ... Cancer Research (AACR) to be held from April ... are related to multiple oncology,programs at Cytokinetics and ...
Cached Medicine Technology:Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment 2Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7
(Date:7/31/2014)... Perhaps some people are unaware of getting ... from the first day when we were born on earth. ... during their whole life. Some people may live without children ... is not necessary for people to worry about that. A ... a famous China automobile manufacturer , is one of ...
(Date:7/31/2014)... 31, 2014 Updox, the industry ... announces the release of a “Twelve Questions to Ask When ... that are evaluating Health Information Service Providers (HISPs) for Direct ... utilize MEDITECH and Epic electronic health records (EHRs) need to ... of care using the Direct protocol. , “Selecting ...
(Date:7/31/2014)... Daily Gossip reveals in its review that the Flat ... weight loss tips. , The author of the new ... simple to implement. Users don’t have to worry, as they ... start counting calories. , The Flat Belly Forever program ... 12 weeks weight loss program to help sufferers model the ...
(Date:7/31/2014)... USHIO America’s Solid State Lighting ... lighting marketplaces, today announced the launch of its ... users to transform existing, inefficient lamp-based downlights to ... USHIO America’s Uphoria LED downlight retrofit kits fit ... the user to upgrade old incandescent recessed lighting ...
(Date:7/31/2014)... Thanks to its mildly sweet ... long been used as a medium for delivery ... fruit. However consistent, dependable sourcing of erythritol often ... food and beverage manufacturers’ increasing needs for reliable, ... GMO-free ErysweetTM Erythritol. , “Erysweet is unique ...
Breaking Medicine News(10 mins):Health News:FodayAuto.com: Do Not Be Afraid of Getting Old 2Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 2Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 3Health News:Updox Introduces Resources to Help Hospitals Choose the Right HISP for Direct Messaging 4Health News:USHIO America Introduces Uphoria™ LED Downlight Retrofit Kits 2Health News:Steviva Ingredients Launches Erysweet Erythritol 2
... Manuscript in March IssueTAMPA, Fla., March 2 ... alfa-2a and ribavirin in patients with chronic hepatitis ... published in the March issue of Gastroenterology, ... Association Institute (AGA Institute). The study showed that ...
... March 2 LCA-Vision Inc. (Nasdaq: ... under the Lasik Plus (R) brand, today announced that members ... James 30th Annual Institutional Investors Conference on Monday, March 9, ... being held at The JW Marriott Grande Lakes Hotel in ...
... Bioniche Life Sciences Inc. (TSX: BNC), a research-based, ... Company has amended the maturity date of its ... (formerly Laurus Master Funds). , On October 31, ... extension of this facility, originally scheduled to mature ...
... to restructure debt -MCLEAN, Va., March 2 Sunrise Senior ... results and operating data for the fourth quarter and the ... webcast Monday, March 2, 2009, at 9:00 a.m. ET, to ... of life for seniors has been Sunrise,s mission since 1981, ...
... Cardiac Science Corporation (Nasdaq: CSCX ), a ... informatics products, announced today that it will release its ... 2009 after the market close. The Company has scheduled ... p.m. Eastern Time. During the call, Cardiac Science ...
... March 2 Alexza Pharmaceuticals, Inc. (Nasdaq: ... Noymer, PhD has been promoted to Vice President, ... position, he will have oversight responsibilities for device ... technology programs.Dr. Noymer joined Alexza in 2006 and ...
Cached Medicine News:Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 2Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 3Health News:Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology 4Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 2Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 3Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 4Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 5Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 6Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 7Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 8Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 9Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 10Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 11Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 12Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 13Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 14Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 15Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 16Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 17Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 18Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 19Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 20Health News:Cardiac Science Schedules Fourth Quarter Earnings Release and Announces Conference Call 2Health News:Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D 2Health News:Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D 3
Solid 14 mm blades. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Open 14 mm blades of heavy 1 mm wire. Dull finish. Most popular size or model....
Open wire style blades allow complete manipulation of the phaco tip inside the eye. Lid control is excellent, exposure is maximized, and the likelihood of positive pressure is reduced....
Medicine Products: